Outlook |
Featured
-
-
Outlook |
Facing the challenge of eliminating hepatitis B
Public-health expert Corinna Dan charts a course to free the United States from the virus.
- Eric Bender
-
Outlook |
Miniature medical robots step out from sci-fi
Tiny machines that deliver therapeutic payloads to precise locations in the body are the stuff of science fiction. But some researchers are trying to turn them into a clinical reality.
- Anthony King
-
News Feature |
Hundreds of COVID trials could provide a deluge of new drugs
Two years into the pandemic, the COVID-19 drugs pipeline is primed to pump out novel treatments — and fresh uses for familiar therapies.
- Heidi Ledford
-
Where I Work |
Going with the gut to understand diseases
Paula Littlejohn researches how nutrients in early life affect long-term health.
- Virginia Gewin
-
Correspondence |
COVID-19: LMICs need antivirals as well as vaccines
- Simar Singh Bajaj
- & Fatima Cody Stanford
-
Outlook |
Ovarian cancer
Survival rates might still be relatively low, but researchers are making valuable inroads into understanding the disease.
- Richard Hodson
-
Outlook |
Innovative therapies to tackle platinum-resistant ovarian cancer
Combining existing drugs with the targeting of biological features of ovarian tumours could extend life when platinum chemotherapy fails.
- Amanda B. Keener
-
Outlook |
What’s next for PARP inhibitors?
After their breakthrough approval for ovarian cancer, attention has turned to how these drugs can benefit more people.
- Simon Makin
-
Outlook |
Reversing blindness with stem cells
Regenerative therapies for the eyes could help to save vision in people with glaucoma, macular degeneration and damaged corneas.
- Neil Savage
-
Outlook |
Stem-cell start-ups seek to crack the mass-production problem
Commercial outfits are building the tools and know-how to manufacture treatments using induced pluripotent stem cells in the quantities required for clinical use.
- Eric Bender
-
Outlook |
Sickle-cell disease
A condition that affects many people of African descent is finally meeting its therapeutic match.
- Herb Brody
-
Outlook |
Can CRISPR cure sickle-cell disease?
Early trials show promise, but the challenge will be reaching those most in need.
-
Outlook |
Gene therapies close in on a cure for sickle-cell disease
As multiple genetic strategies advance through the clinic, important safety questions remain to be answered.
- Michael Eisenstein
-
Outlook |
No adult left behind: bridge the health-care gap for sickle-cell disease
The United States has reduced child mortality from this condition — but comprehensive care for adults has not kept pace.
- Julian Nowogrodzki
-
Outlook |
The sickle-cell drug boon
A growing number of promising treatments is set to bring hope to people living with the disease.
- Benjamin Plackett
-
Outlook |
Why severe sickle-cell pain has been neglected
Pain in sickle-cell disease is poorly understood — and patients face both medical and socioeconomic problems when seeking delivery from discomfort.
- Bianca Nogrady
-
Outlook |
Autoimmune disease
When the body becomes the target of its own defensive arsenal, medicine must step in.
- Richard Hodson
-
Outlook |
Alopecia areata: why the battle isn’t over
Molecular geneticist Angela Christiano explains why one treatment is not enough for this neglected autoimmune disease that causes hair loss.
- Laura Vargas-Parada
-
Outlook |
Creating T cells to guard against autoimmune disease
Biotechnology companies are engineering regulatory T cells to help protect the body from friendly fire.
- Eric Bender
-
Outlook |
Bioelectronic devices could treat autoimmune disease
Neurosurgeon Kevin J. Tracey talks to Nature about controlling inflammation in rheumatoid arthritis by stimulating the vagus nerve.
- Julianna Photopoulos
-
Outlook |
A drug to block fat intake and combat cancer spread
The start-up ONA Therapeutics is developing an antibody directed at cells that initiate metastasis in cancer.
- Elie Dolgin
-
-
News |
International COVID-19 trial to restart with focus on immune responses
World Health Organization will test whether three existing drugs can save lives of hospitalized people.
- Heidi Ledford
-
Correspondence |
Pool patents to get COVID vaccines and drugs to all
- Etienne Billette de Villemeur
- , Vianney Dequiedt
- & Bruno Versaevel
-
Outline |
The skin microbiome
The skin supports a diverse community of microorganisms that train and support the immune system, and fend off pathogenic threats.
- Michael Eisenstein
-
Outlook |
The drug that could save the lives of many women
Misoprostol can prevent and treat postpartum haemorrhage. But because it can also cause abortions, availability of the cheap medication is often tightly restricted.
- Alla Katsnelson
-
Outlook |
Outlook: Multiple myeloma
Advances in treatment and a better understanding of the cancer mean people with the disease are living longer.
- Brian Owens
-
Outlook |
Immunotherapies target multiple myeloma
Treatments that help the immune system fight multiple myeloma are emerging fast, but the number of people who relapse remains.
- Dalmeet Singh Chawla
-
Outlook |
Burning questions about smouldering myeloma
Researchers are amassing evidence about the best ways to treat the precursor condition before it develops into active disease.
- Sarah DeWeerdt
-
Outlook |
Scientists are harnessing viruses to treat tumours
Could viruses such as the one used in the measles vaccine be used to treat multiple myeloma?
- Carolyn Brown
-
Outlook |
Lung cancer
There is encouraging news in the fight against the world’s most deadly form of cancer.
- Herb Brody
-
Outlook |
Research round-up: lung cancer
Refining immunotherapy, evaluating the benefits of screening, and other highlights from clinical trials and laboratory studies.
- Bianca Nogrady
-
Outlook |
Lung-cancer researchers and clinicians must pay more attention to women
It is not a disease just for old men any more.
- Narjust Duma
-
Outlook |
The screening imperative for multiple myeloma
S. Vincent Rajkumar says there is enough evidence to begin testing, and treating, people at high risk of the disease much earlier.
- S. Vincent Rajkumar
-
Outlook |
Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer
Communities sharing particular types of the disease are helping steer research towards better therapies.
- Elie Dolgin
-
Outlook |
Better treatments for lung cancer that spreads to the brain
Metastasis to the brain is usually a swift death sentence but researchers are developing ways to make it less lethal.
- Natalie Healey
-
News Feature |
Why do COVID death rates seem to be falling?
Hard-won experience, changing demographics and reduced strain on hospitals are all possibilities — but no one knows how long the change will last.
- Heidi Ledford
-
Correspondence |
Non-animal-derived antibodies: pharma companies respond
- Matt Truppo
- , George Yancopoulos
- & Ivo Lorenz
-
Outlook |
Treating headache to save sight
Neurologist Alexandra Sinclair explains why intracranial hypertension is a condition of concern — on this planet and beyond.
- Julianna Photopoulos
-
Outlook |
A visual guide to migraine headaches
The pain, the pressure, the way it ruins your mood — everyone has experienced a headache at one time or another. But whereas most are transient and easily managed, migraines are stubborn and debilitating.
- Neil Savage
-
Outlook |
The unique demands of childhood migraine
How researchers think about migraine in young people is shifting, offering hope for better long-term management of the condition.
- Emily Sohn
-
Outlook |
Research round-up: headache
A new target for migraine treatments, electrical stimulation for cluster headache, and other highlights from clinical trials and laboratory studies.
- Anthony King
-
Outlook |
A new generation of headache drugs
Monoclonal antibodies and small-molecule antagonists that target CGRP or its receptor are already having a big impact on migraine. But they have the potential to do so much more.
- Marcus Woo
-
Outlook |
Building better CAR-T therapies
The current technique requires a person’s own cells, but using the cells of healthy donors could allow more people to benefit.
- Anthony King
-
Outlook |
The future of tissue-agnostic drugs
Some people with cancer are already benefiting from drugs that target genetic features regardless of the tissue involved. But these early successes could be the exceptions.
- Julianna Photopoulos
-
Outlook |
Cystic fibrosis
Innovative therapies are bringing hope to people with this inherited lung disorder.
- Herb Brody
-
Outlook |
Bacteria-eating viruses could provide a route to stability in cystic fibrosis
Phage therapy is broadening the treatment landscape for people with drug-resistant infections.
- Elizabeth Svoboda
-
Outlook |
Gene therapy could offer an inclusive cure for cystic fibrosis
After three decades of false starts, gene therapy against the disease is in new clinical trials — and there is even hope of a cure.
- Roxanne Khamsi
-
Outlook |
How much protein function needs to be restored in cystic fibrosis?
Knowing the percentage of function that is required to eliminate disease symptoms could help to shape treatment in the coming years and ensure sufferers don’t slip through the net.
- Benjamin Plackett
Browse broader subjects
Browse narrower subjects
- Adverse effects
- Biological therapy
- Bisphosphonates
- Cardiac device therapy
- Drug therapy
- Gene therapy
- Hormonal therapies
- Immunotherapy
- Interventional cardiology
- Nutrition therapy
- Pain management
- Palliative care
- Placebo effect
- Radiotherapy
- Rehabilitation
- Renal replacement therapy
- Reproductive techniques
- Stem-cell therapies
- Surgery
- Therapeutic endoscopy